CHICAGO, October 14, 2024 — Vyaire Medical today announced that it has completed the sale of Vyaire Ventilation Business Unit to ZOLL Medical Corporation, a global leader in acute critical care and related software and diagnostic tools. Certain Ventilation assets were not included in the sale to ZOLL.

“We are pleased to deliver on our commitment to sell our Ventilation Business Unit to a well-capitalized buyer who can support the growth and development of the Vyaire Ventilation product portfolio,” said John Bibb, Group Chief Executive Officer, Vyaire. “Vyaire will continue to work closely with ZOLL to ensure a smooth transition for our team members, customers, and partners.”

Under the terms of the agreement, ZOLL will acquire the bellavista™, fabian™, LTV™, and 3100 HFOV product lines, along with associated consumables, service parts, accessories, and service program offerings. ZOLL also acquired Vyaire’s existing inventory of AVEA™, ReVel™, SiPAP, and VELA™ ventilators and Vyaire MicroBlenders. 

The sale to ZOLL does not include the iX5™ ventilator product line and associated operations, which Vyaire is marketing to other interested bidders. Vyaire continues to fully manage its RDx business and products, with full support to customers. The company anticipates closing the sale of its RDx Business Unit to Trudell Medical Limited in the coming weeks. 

_________________________________

About Vyaire Medical

Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 70-year history of pioneering breathing technology, the integrated solutions offered by the company’s Ventilation and Respiratory Diagnostics (RDx) businesses help enable, enhance, and extend lives. Vyaire products are available in more than 100 countries and are recognized, trusted, and preferred by specialists throughout the respiratory community worldwide.